Soliris approved in China for the treatment of adults with neuromyelitis optica spectrum disorder (NMOSD) The approval by the National Medical Products Administration (NMPA) in China was based on results from the Phase III PREVENT trial.1 In the trial, Soliris met the primary…
AMGEN TO WEBCAST INVESTOR CALL AT ESMO 2023 Amgen (NASDAQ:AMGN) today announced that it will host a webcasted call for the investment community at 8:00 a.m. ET on Tuesday, Oct. 24, 2023 following the presentation of new data from Amgen’s innovative oncology portfolio including AMG 193…
Gilead Sciences Announces New Clinical Trial in Europe to Assess Lenacapavir for HIV Prevention as Part of Landmark Purpose Program Gilead Sciences, Inc. (Nasdaq: GILD) today announced PURPOSE 5, the first Phase 2 clinical trial to evaluate an investigational long-acting…
Gilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases Gilead Sciences, Inc. (Nasdaq: GILD) and Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced that the…
TOGETHER FOR CHANGE GENOMICS AND EQUITY INITIATIVE LAUNCHED BY A COALITION OF MEHARRY MEDICAL COLLEGE, REGENERON GENETICS CENTER, ASTRAZENECA, NOVO NORDISK, AND ROCHE TO IMPROVE HEALTH OUTCOMES FOR PEOPLE OF AFRICAN ANCESTRY NASHVILLE, Tenn. and TARRYTOWN, N.Y. and WILMINGTON, Del. and BAGSVAERD, Denmark and BASEL, Switzerland, Oct. 18, 2023 (GLOBE…
R&D Postdoctoral Challenge is a ground-breaking initiative fostering collaboration, innovation and global diversity AstraZeneca announced today eight winners of the 2023 R&D Postdoctoral Challenge and agreed to fund their postdoctoral positions at one of the Company’s strategic R&D centres in either Cambridge,…
U.S. FDA Approves Pfizer’s BRAFTOVI® + MEKTOVI® for BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) for the treatment of adult patients…
Bayer invests 250 million USD in new cell therapy manufacturing facility in the U.S. Bayer AG has opened a new cell therapy production plant in Berkeley, California, USA, to bring cell therapies to patients on a global scale. The USD…
Merck Highlights Innovative Oncology Portfolio and Pipeline at ESMO Congress 2023 Underscoring Commitment to Advancing Cancer Research and Improving Patient Outcomes Across Multiple Stages of Disease Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today…
Roche’s Vabysmo maintained vision improvements with extended treatment intervals up to four months for people with retinal vein occlusion (RVO) in phase III studies Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive topline long-term results from the global phase…
Amylyx Pharmaceuticals Provides Update on Accès Compassionnel for AMX0035 in France L’Agence Nationale de Sécurité du Médicament et des produits de santé (ANSM), the national authority for authorizing medicinal products in France, has granted “accès compassionnel” (compassionate access) to AMX0035…
Thermo Fisher Scientific Expands St. Louis Manufacturing for Complex Biologic Treatments Thermo Fisher Scientific, the world leader in serving science, today expanded its manufacturing capacity in St. Louis to support biologic therapies for diseases ranging from cancers to auto immune…